Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.

The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.

Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.

For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.